	Reply to T. Takahashi's Letter to the Editor re: Re: Nguyen DD, Tadayon Najafabadi B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol. In press. Eur Urol Nguyen DD, Najafabadi BT, Rosella LC, Dahm P, Guyatt GH, Kulkarni GS. PMID: 42716822 [PubMed - as supplied by publisher]
	Risk Stratification in Non-Muscle-Invasive Bladder Cancer in the Era of Expanding Therapeutic Options: Are Current Classifications Still Adequate? Fr J Urol Duquesne I, Chakra MA, de la Taille A, O'Donnell MA, Pignot G. PMID: 42716474 [PubMed - as supplied by publisher]
	Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era. Lancet Oncol Richters A, Bond MJG, Westgeest HM, Özdemir BC, Damen JAA, Aben KKH, Bex A. PMID: 42716079 [PubMed - as supplied by publisher]
	Prospective Evaluation of Circulating Tumor DNA in Metastatic Hormone-Sensitive Prostate Cancer. JCO Precis Oncol Nguyen CB, Tsung I, Lee JK, Pasquina LW, Kasputis A, Lovett JL, Graf RP, Redmond A, Cackowski FC, Heath EI, Smith DC, Alumkal JJ, Morgan TM, Reichert ZR. PMID: 42715508 [PubMed - indexed for MEDLINE]
	Uncovering the diagnostic potential of seminal fluid beyond fertility: cfDNA methylation analysis for the detection of clinically significant prostate cancer. PLoS One Geis J, Smith JF, Maddala T, Thoreson G, Michel K, Kaminetsky J, Belkoff L, Huang S, Griscom B, Hart JC, Bench S, Ardalani H, Rivas-Yepes L, Civello D, Clark-Langone KM. PMID: 42715227 [PubMed - indexed for MEDLINE]
	Immune-checkpoint inhibitor-induced bullous pemphigoid in patients with metastatic renal cell carcinoma: two case reports and systematic review of the literature. Acta Oncol Filis P, Lindskog M, Curman P, Kuzmina N, Krantz Å, Chatzidionysiou K, Costa Svedman F, Zerdes I. PMID: 42714143 [PubMed - indexed for MEDLINE]
	PD09-07 Durvalumab in Combination with Bacillus Calmette-GuÃ©rin for Bacillus Calmette-GuÃ©rin-NaÃ¯ve, High-Risk Non-Muscle-Invasive Bladder Cancer: Primary Results from a US-Based, Phase IIIB, Open-Label, Single-Arm, Multicenter Study (PATAPSCO): Erratum. J Urol Jayram G, Shore ND, Tyson M, Pieczonka C, Treasure P, Gadzinski A, Mazzarella B, Hodari M, Glover K, Hardikar S, Hahn NM. PMID: 42713894 [PubMed - in process]
	Predicting postoperative acute kidney injury after colorectal cancer surgery: development and internal validation of a clinical prediction model using a nationwide cohort. BJS Open Skovsgaard M, Munch PV, Heide-Jørgensen U, Iversen LH, Christiansen CF. PMID: 42713840 [PubMed - indexed for MEDLINE]
	Comparison of Beiyi(Â®) and its reference product Enantone(Â®) as agonists of luteinizing hormone-releasing hormone against prostate cancer: a multicenter, randomized single-dose study. Front Pharmacol Yi Y, Shen P, Zheng T, Hou R, Fan L, Yu Y, Li J, Fang Y, Hao C, You P, Lu X, Lu X, Wei Q, Feng P. PMID: 42713047 [PubMed]
	Prognostic effect of the preoperative albumin-to-globulin ratio bladder cancer: a meta-analysis. Front Med (Lausanne) Huang F, Chen C, Mao Y, Lin T, Hu Q. PMID: 42712354 [PubMed]
	Metal artifact reduction for 3 T MRI-only prostate radiotherapy in patients with hip prostheses: impact on target definition, synthetic CT generation, dose calculation, and fiducial marker identification. Radiat Oncol Coskun M, Petersson JS, Wetterstedt SA, Brynolfsson P, Gustafsson CJ, Gunnlaugsson A, Olsson LE, Siversson C. PMID: 42711722 [PubMed - indexed for MEDLINE]
	Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform. Eur Urol Gray S, Dutey-Magni P, Jones C, Murphy LR, Murray ML, Brown JE, McCloskey E, Brown M, Amos CL, Gilbert DC, Jones RJ, Cross W, Matheson D, Millman R, STAMPEDE Collaborators, Parmar MKB, Sydes MR, Brown LC, Attard G, James ND, Clarke NW, Sachdeva A. PMID: 42711192 [PubMed - as supplied by publisher]
	Epidemiological trends in penile cancer and the evolving role of dynamic sentinel lymph node biopsy. Urol Oncol Hehir CM, Scanlon L, Calpin GG, Cullen IM. PMID: 42711149 [PubMed - as supplied by publisher]
	Detected Huge Urinoma With 99mTc-PSMA Activity on Initial Prostate Cancer Staging. Clin Nucl Med Ahmadi M, Samadi MH, Saber Tanha A, Askari E, Aslzare M, Dabbagh Kakhki VR. PMID: 42710082 [PubMed - indexed for MEDLINE]
	Graph neural network-based risk stratification of prostate cancer using gene expression and SHAP interpretability. PLoS One Pirmoradi S, Vaghefi Moghaddam S, Ardalan M, Sharifi Bonab MM, Teshnehlab M, Zununi Vahed S. PMID: 42709904 [PubMed - indexed for MEDLINE]
	Deep learning for automatic detection of prostatectomy in CT images of prostate cancer patients. Phys Eng Sci Med Rainio O, Li A, Vehmanen A, Jaakkola MK, Kemppainen J, Klén R. PMID: 42709364 [PubMed - as supplied by publisher]
	Refining risk stratification after indeterminate urinary cytology: Evidence from Bladder EpiCheck. Cancer Cytopathol Mercader C, Ingelmo-Torres M, Roldán FL, Figueras M, Villalba E, Galve P, Asiaín I, Costa M, Vilaseca A, Oriola J, Franco A, Alcaraz A, Mengual L. PMID: 42708821 [PubMed - indexed for MEDLINE]
	Research progress and clinical translation prospects of the urinary tract microbiome in prostate cancer. Front Immunol Li ZL, Qu RN, Liu SX, Wang W. PMID: 42707980 [PubMed - indexed for MEDLINE]
	Urinary Trace Element Concentrations in Congolese Patients With Prostate Cancer: A Case-Control Study. Prostate Cancer Mbey PM, Mukuku O, Saleh CU, Manika MM, Diangienda PDK, Moningo DM. PMID: 42707973 [PubMed]
	Frailty and [(177)Lu]Lu-PSMA-617 therapy: tools and strategies for older men with metastatic castration-resistant prostate cancer. Theranostics Bauckneht M, Borsellino N, Colloca GF, Fratino L, Santini D. PMID: 42707638 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 181325

Page 1 of 9067



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy